Corey Williams
Corey Williams's Latest Posts
SET Monthly Issue March 2014
March 2014 PLAYING RUSSIAN ROULETTE Tensions are running high as Russian troops remain in control of the Crimea region of Ukraine. Russian President Putin hasn’t given any indication he’s going to back down. Now there’s the very real possibility of UN and US sanctions against the former Super Power. There’s no doubt about it, these […]
EOT position update March 12, 2014
March 12, 2014 Market Snapshot It’s been a quiet week on Wall Street with little in the way of economic news. The lack of any catalyst to move the market has sent the S&P 500 drifting lower since reaching a new all-time high of 1,883 on Friday. A slew of economic data will be released […]
EOT trade alert March 11, 2014
March 11, 2014 Trade Alert: Buy GILD April 2014 $82.50 Calls at $2.45 or better Company Background: Gilead Sciences (GILD) is a biopharmaceutical company. They specialize in the discovery, development, and commercialization of medicines to treat life threatening diseases. Short-Term Catalyst: The raging bull market just won’t quit. Biotechnology is one of, if not the […]
BST Position Update: March 11, 2014
March 11, 2014 . . . . Lpath (NASDAQ: LPTN) – Buy up to $5.30 LPTN was added to the portfolio a few days ago. This fascinating biotech is pioneering a new approach to drug development using lipidomics and its ImmuneY2 technology. The company’s leading drug candidate is a monoclonal antibody called iSONEP that is […]
BST Trade Alert: March 7, 2014
March 7, 2014 Recommendation: Buy Lpath (NASDAQ: LPTN) up to $5.30 per share. About the Company: Lpath is a fascinating biotech that has enormous potential. With its unique technology and scientific expertise, this tiny company is pioneering an entirely new approach to drug development. And if this new approach bears fruit, Lpath could become a new leader […]
EOT position update March 5, 2014
March 5, 2014 Market Snapshot Just last week the S&P 500 and many other market indexes reached new all-time highs. The rally was being spurred on by a boat load of better than expected economic data. Housing prices, new home sales, durable goods, Chicago PMI, University of Michigan Confidence, and bank lending all surprised investors […]
SET Portfolio Update March 2014
March 4, 2014 It’s been quite a month since our last portfolio update. At the time, stocks were in the midst of a dramatic correction. Investor sentiment had swung to extreme levels of fear and a bearish outlook for stocks was the prevailing attitude. Then with little or no warning, the stock market selloff stopped, […]
EOT position update February 26, 2014
February 26, 2014 Market Snapshot The bull market is strong… The January pullback was met with an even stronger recovery. The S&P 500 now stands at a new high after eclipsing the previous high of 1,850 set on January 15th. The charge is being led higher by risky and aggressive stocks like Google (GOOG),Tesla Motors […]
BST Position Update: February 26, 2014
February 26, 2014 . . . . Acasti Pharma (NASDAQ: ACST) – Buy up to $1.40 Acasti is our most recent addition to the portfolio. This exciting biotech is developing CaPre for the prevention and treatment of hypertriglyceridemia. CaPre is a highly purified omega-3 phospholipid concentrate derived from krill oil. We’re excited about CaPre because […]
BST Trade Alert: February 20, 2014
February 20, 2014 Recommendation: Buy Acasti Pharma (NASDAQ: ACST) up to $1.40 per share. About the Company: Acasti is a Canadian biotech focusing on the development of new therapies for dyslipidemia (abnormalities in blood lipids) and cardiovascular disorders. It was founded in 2002 and is a subsidiary of Neptune Technologies & Bioresources(NASDAQ: NEPT). The key to the company’s […]
